COMP <GO>
CBLL vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
CeriBell Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CBLL 4
— MRK 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $27.82 (+2.20%) • MKT CAP: $1.07B
roic
-35.00%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBLL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBLL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 74.80% | +13.10 | CBLL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.89% | 3.42% | -7.31 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 36.10% | 1.30% | +34.80 | CBLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.75 | 5.19 | +9.56 | CBLL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.0 | 51.7 | +2.34 | CBLL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.07B | $361.02B | -$359.95B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBLL REV | MRK REV | CBLL GROSS % | MRK GROSS % | CBLL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $89.1M | $65.01B | 87.9% | 74.8% | -$41.6M | $12.36B |
| FY 2024 | $65.4M | $64.17B | 86.7% | 76.3% | -$36.4M | $18.10B |
| FY 2023 | $45.2M | $60.12B | — | — | -$29.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBLL // BETA —
MRK // BETA 0.92